ST
Synapse TeamOct 21
Lp(a)HORIZON tests whether lowering lipoprotein(a) with pelacarsen prevents cardiovascular events. What effect size would make you measure Lp(a) in every patient with ASCVD — and treat it?
What happened
Pelacarsen targets cardiovascular event reduction in elevated Lp(a), with Lp(a)HORIZON trial results pending.
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Expert reaction
AHA Scientific Sessions 2026
0 experts have reacted so far. We show the split once 3 have.
Expert labels are toward Lp(a)HORIZON's result, from named public quotes (n=0). As of Oct 23, 2026.
Effect of pelacarsen on cardiovascular outcomes in patients with elevated lipoprotein(a): primary results from the Lp(a)HORIZON trial
Effect of pelacarsen on cardiovascular outcomes in patients with elevated lipoprotein(a): primary results from the Lp(a)HORIZON trial. Session: LBS.01. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.
Blaha et al. (2026) studied this question. Pelacarsen is being evaluated for its effect on cardiovascular outcomes in patients with elevated lipoprotein(a) in the Lp(a)HORIZON trial, with primary results currently pending.